share_log

Stifel Initiates Coverage On Cullinan Therapeutics With Buy Rating, Announces Price Target of $40

Benzinga ·  May 1 05:49

Stifel analyst Bradley Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $40.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment